Impact of managed care on the use of biologic agents for rheumatoid arthritis

Arthritis Care and Research

Volumn 53, Issue 3, 2005, Pages 423-430

  Yelin, Edward H ^a   Trupin, Laura S ^a   Katz, Patricia P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic agents; Managed care; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ARTICLE; FEMALE; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HUMAN; INSTRUMENT; INTERVIEW; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL FEE; OUTCOMES RESEARCH; RHEUMATOID ARTHRITIS; UNITED STATES;

ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CALIFORNIA; CYCLOOXYGENASE INHIBITORS; FEE-FOR-SERVICE PLANS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INTERVIEWS; MALE; MANAGED CARE PROGRAMS; METHOTREXATE; MIDDLE AGED;

EID: 20444406489     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21178     Document Type: Article

References (35)

1. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
2. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
3. Moreland L. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004;22(Suppl 2):39-53.
4. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.
5. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
6. Cohen SB, Woolley JM, Chan W, and the Anakinra 960180 Study Group. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 2003;30:225-31.
7. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA Trial. Arthritis Rheum 2003; 48:35-45.
8. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
9. Medical Economics Staff. 1999 Red Book. Montvale (NJ): Medical Economics Company; 1999.
10. Gabel J, Claxton G, Holve E, Pickreign J, Whitmore H, Dhont K, et al. Health benefits in 2003: premiums reach thirteen-year high as employers adopt new forms of cost sharing. Health Aff (Millwood) 2003;22:117-26.
11. Jensen GA, Morrisey MA, Gaffney S, Liston DK. The new dominance of managed care: insurance trends in the 1990s. Health Aff (Millwood) 1997;16:125-36.
12. US Health Care Finance Administration. 2000 Medicaid managed care enrollment report HCFA. Baltimore (MD): Centers for Medicare & Medicaid Services; 2000.
13. US Bureau of the Census. Statistical abstract of the United States, 2002. Washington (DC): USGPO; 2002.
14. Miller R, Luft H. Managed care plan performance: evidence from recently published studies. In: Speech before American Association of Health Plans. Series Managed care plan performance: Evidence from recently published studies. 1997.
15. Sullivan K. On the 'efficiency' of managed care plans. Health Aff (Millwood) 2000;19:139-48.
16. Ware JE Jr, Bayliss MS, Rogers WH, Kosinski M, Tarlov AR. Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems: results from the Medical Outcomes Study. JAMA 1996;276:1039-47.
17. Yelin E. Managed care and rheumatoid arthritis. In: Manning F, Barondess J, editors. Changing health care systems and rheumatic disease: a report of the Institute of Medicine. Washington (DC): National Academy of Sciences Press; 1996.
18. Lubeck DP, Brown BW, Holman HR. Chronic disease and health system performance: care of osteoarthritis across three health services. Med Care 1985;23:266-77.
19. Yelin EH, Shearn MA, Epstein WV. Health outcomes for a chronic disease in prepaid group practice and fee for service settings. Med Care 1986;24:236-47.
20. Yelin E, Trupin L, Katz P. The prevalence and impact of managed care for persons with rheumatoid arthritis in 1994 and 1999. Arthritis Rheum 2002;47:172-80.
21. Ward MM, Lubeck D, Leigh JP. Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings. J Rheumatol 1998;25:641-9.
22. Weiner JP, de Lissovoy G. Razing a tower of Babel: a taxonomy for managed care and health insurance plans. J Health Polit Policy Law 1993;18:75-103.
23. Miller RH, Luft HS. Managed care plan performance since 1980: a literature analysis. JAMA 1994;271:1512-9.
24. Kerwin J, Cantor D, Sheridan S. Results of rounds 3 and 4 of managed care cognitive interviews for the household portion of the MEPS report to AHCPR from Westat, Inc, March 7, 1995, Rockville (MD): Westat, Inc.;
25. Kovar M, Poe G. National Health Interview Survey Design, 1973-1984 and Procedures, 1975-1983. Vital and Health Statistics 1985; Series 1 (Number 18).
26. Katz PP, Alfieri WS. Satisfaction with abilities and well-being: development and validation of a questionnaire for use among persons with rheumatoid arthritis. Arthritis Care Res 1997;10:89-98.
27. Yelin EH, Henke CJ, Kramer JS, Nevitt MC, Shearn M, Epstein WV. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. N Engl J Med 1985;312:962-7.
28. Yelin E, Lubeck D, Holman H, Epstein W. The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with rheumatoid arthritis and osteoarthritis compared to controls. J Rheumatol 1987;14:710-7.
29. Research Triangle Institute. SUDAAN user's manual, release 8.0. In: Series SUDAAN user's manual, release 8.0. Research Triangle Park (NC): Research Triangle Institute; 2001.
30. Manning F, Barondess J, editors. Changing health care systems and rheumatic disease: a report of the institute of medicine. Washington (DC): National Academy of Sciences Press; 1996.
31. Manheim LM. Managed care and arthritis care: patients and providers under the new medical care organizations. Arthritis Care Res 1995;8:298-303.
32. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62.
33. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
34. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
35. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3046-54.